ReviewNeuro-oncology advances
Clinical characteristics and outcomes of adult IDH-mutant brainstem gliomas: Institutional case series and systematic review.
Review in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Adult IDH-mutant brainstem gliomas (BSGs) are rare and appear molecularly distinct from H3K27-altered diffuse midline gliomas. We aimed to provide a comprehensive characterization by integrating an institutional cohort with a pooled individual-patient analysis. Methods: Adults with IDH-mutant BSGs diagnosed at our institution were identified. A PRISMA-guided search of PubMed and Scopus captured additional cases. Individual-level demographic, radiographic, molecular, treatment, and outcome data were abstracted. Kaplan-Meier and log-rank testing evaluated survival associations with age, sex, WHO grade, surgery, chemoradiation, IDH variant, MGMT methylation, ATRX status, and location. Results: Eighty-four patients were analyzed ( Conclusions: Adult IDH-mutant BSGs represent a clinically meaningful subgroup with outcomes more favorable than H3K27-altered gliomas but shorter than supratentorial IDH-mutant gliomas. Their recurrent molecular features, including frequent non-canonical IDH variants, warrant study in larger cohorts to clarify biological significance, refine prognostication, and inform the potential role of IDH-targeted therapies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.